Attorney Docket No.: 5470-276

Serial No. 10/069,305 Filed: June 6, 2002

Page 2 of 6

Listing of Claims:

Please amend the claims as shown below. This listing of claims will replace all prior versions and listings of the claims in this application.

1-26. (Canceled)

- 27. (Currently amended) A method of administering a nucleotide sequence to a subject, comprising:
- (a) administering a Venezuelan Equine Encephalitis (VEE) vector comprising a heterologous nucleotide sequence to a subject; and
- (b) administering an antibody that specifically binds to the E1 glycoprotein and/or the E2 glycoprotein of the VEE vector to the subject;

wherein said administering steps of (a) and (b) are concurrent;

whereby the heterologous nucleotide sequence is introduced into and expressed in the subject.

- 28. (Original) The method of Claim 27, wherein there is no significant pathology in the subject as a result of said administering steps.
- 29. (Original) The method of Claim 27, wherein the subject is selected from the group consisting of primate, bovine, ovine, caprine, porcine, equine, feline, canine, lagomorph, and rodent subjects.
 - 30. (Original) The method of Claim 29, wherein the subject is a human subject.
 - 31. Canceled.
- 32. (Currently amended) The method of Claim [[31]]27, wherein the VEE vector and the antibody are administered in a single formulation.

33-45. (Canceled).

Attorney Docket No.: 5470-276

Serial No. 10/069,305 Filed: June 6, 2002

Page 3 of 6

- 46. (New) A method of administering a nucleotide sequence to a subject, comprising:
- (a) administering a Venezuelan Equine Encephalitis (VEE) vector comprising a heterologous nucleotide sequence to a subject; and
- (b) administering an antibody that specifically binds to the E1 glycoprotein and/or the E2 glycoprotein of the VEE vector to the subject;

wherein the antibody is administered prior to the VEE vector;

whereby the heterologous nucleotide sequence is introduced into and expressed in the subject.

- 47. (New) The method of Claim 46, wherein there is no significant pathology in the subject as a result of said administering steps.
- 48. (New) The method of Claim 46, wherein the subject is selected from the group consisting of primate, bovine, ovine, caprine, porcine, equine, feline, canine, lagomorph, and rodent subjects.
 - 49. (New) The method of Claim 48, wherein the subject is a human subject.